Pathios Therapeutics

Executive Summary

Pathios Therapeutics is a clinical-stage oncology and immunology company pioneering a novel macrophage conditioning approach to target the acid-sensing G protein-coupled receptor GPR65. The company's lead program is an oral GPR65 inhibitor designed to counteract the immunosuppressive tumor microenvironment, with first-in-class potential across multiple solid tumors. Founded in 2017 and based in Oxford, UK, Pathios is advancing its preclinical pipeline toward clinical development. The GPR65 target is genetically validated, offering a promising mechanism to reprogram tumor-associated macrophages and enhance anti-tumor immunity. As a private company, Pathios has not disclosed its funding rounds, but its innovative approach and clear scientific rationale position it as a potential leader in immuno-oncology. The company's progress to date is preclinical, but the strong genetic validation of GPR65 and the urgent need for novel immunomodulatory agents in solid tumors provide a solid foundation for future clinical trials. Pathios' oral GPR65 inhibitor could offer a differentiated, convenient therapeutic option compared to existing injectable immunotherapies. The near-term focus will be on completing IND-enabling studies and initiating first-in-human trials. If successful, Pathios could address significant unmet need in cancers resistant to current checkpoint inhibitors. The company's unique macrophage conditioning strategy sets it apart in the competitive immuno-oncology landscape.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for GPR65 Inhibitor70% success
• Q1 2027Phase 1 Trial Initiation65% success
• Q3 2026Preclinical Efficacy Data at Major Conference80% success